Cargando…

Serodiagnosis of Anti-glomerular Basement Membrane Disease Using a Newly Developed Chemiluminescence Immunoassay

Circulating autoantibodies directed against the kidney glomerular basement membrane (GBM) antigens are important markers in the diagnosis and monitoring of autoimmune glomerulonephritides, including the classic Goodpasture's syndrome. Rapid and reliable diagnostic tools for the detection of ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Kühnl, Alexander, Hartwig, Lea, Dähnrich, Cornelia, Schlumberger, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289136/
https://www.ncbi.nlm.nih.gov/pubmed/35860736
http://dx.doi.org/10.3389/fmed.2022.915754
_version_ 1784748595922075648
author Kühnl, Alexander
Hartwig, Lea
Dähnrich, Cornelia
Schlumberger, Wolfgang
author_facet Kühnl, Alexander
Hartwig, Lea
Dähnrich, Cornelia
Schlumberger, Wolfgang
author_sort Kühnl, Alexander
collection PubMed
description Circulating autoantibodies directed against the kidney glomerular basement membrane (GBM) antigens are important markers in the diagnosis and monitoring of autoimmune glomerulonephritides, including the classic Goodpasture's syndrome. Rapid and reliable diagnostic tools for the detection of anti-GBM autoantibodies are crucial as anti-GBM disease can progress rapidly and, if too late or incorrectly diagnosed, can have serious, even fatal consequences. The performance of the newly developed standardized chemiluminescence immunoassay (ChLIA) was evaluated in comparison with the established Anti-GBM ELISA (IgG) (EUROIMMUN). For the assessment of its diagnostic performance, sera from 67 clinically characterized anti-GBM disease patients and 221 disease controls were analyzed. The clinical sensitivity of the Anti-GBM ChLIA (IgG) reached 100% at a specificity of 98.6%. The Anti-GBM ELISA (IgG) performance was less sensitive (89.6%) without any positive findings in the control group, indicating a specificity of 100%. Both methods were homogeneous (κ = 0.901). The Anti-GBM ChLIA (IgG) represents a promising alternative tool for accurate anti-GBM assessment in routine diagnostic settings with the advantage of rapid turnaround time and fully automated random-access processing.
format Online
Article
Text
id pubmed-9289136
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92891362022-07-19 Serodiagnosis of Anti-glomerular Basement Membrane Disease Using a Newly Developed Chemiluminescence Immunoassay Kühnl, Alexander Hartwig, Lea Dähnrich, Cornelia Schlumberger, Wolfgang Front Med (Lausanne) Medicine Circulating autoantibodies directed against the kidney glomerular basement membrane (GBM) antigens are important markers in the diagnosis and monitoring of autoimmune glomerulonephritides, including the classic Goodpasture's syndrome. Rapid and reliable diagnostic tools for the detection of anti-GBM autoantibodies are crucial as anti-GBM disease can progress rapidly and, if too late or incorrectly diagnosed, can have serious, even fatal consequences. The performance of the newly developed standardized chemiluminescence immunoassay (ChLIA) was evaluated in comparison with the established Anti-GBM ELISA (IgG) (EUROIMMUN). For the assessment of its diagnostic performance, sera from 67 clinically characterized anti-GBM disease patients and 221 disease controls were analyzed. The clinical sensitivity of the Anti-GBM ChLIA (IgG) reached 100% at a specificity of 98.6%. The Anti-GBM ELISA (IgG) performance was less sensitive (89.6%) without any positive findings in the control group, indicating a specificity of 100%. Both methods were homogeneous (κ = 0.901). The Anti-GBM ChLIA (IgG) represents a promising alternative tool for accurate anti-GBM assessment in routine diagnostic settings with the advantage of rapid turnaround time and fully automated random-access processing. Frontiers Media S.A. 2022-07-04 /pmc/articles/PMC9289136/ /pubmed/35860736 http://dx.doi.org/10.3389/fmed.2022.915754 Text en Copyright © 2022 Kühnl, Hartwig, Dähnrich and Schlumberger. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Kühnl, Alexander
Hartwig, Lea
Dähnrich, Cornelia
Schlumberger, Wolfgang
Serodiagnosis of Anti-glomerular Basement Membrane Disease Using a Newly Developed Chemiluminescence Immunoassay
title Serodiagnosis of Anti-glomerular Basement Membrane Disease Using a Newly Developed Chemiluminescence Immunoassay
title_full Serodiagnosis of Anti-glomerular Basement Membrane Disease Using a Newly Developed Chemiluminescence Immunoassay
title_fullStr Serodiagnosis of Anti-glomerular Basement Membrane Disease Using a Newly Developed Chemiluminescence Immunoassay
title_full_unstemmed Serodiagnosis of Anti-glomerular Basement Membrane Disease Using a Newly Developed Chemiluminescence Immunoassay
title_short Serodiagnosis of Anti-glomerular Basement Membrane Disease Using a Newly Developed Chemiluminescence Immunoassay
title_sort serodiagnosis of anti-glomerular basement membrane disease using a newly developed chemiluminescence immunoassay
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289136/
https://www.ncbi.nlm.nih.gov/pubmed/35860736
http://dx.doi.org/10.3389/fmed.2022.915754
work_keys_str_mv AT kuhnlalexander serodiagnosisofantiglomerularbasementmembranediseaseusinganewlydevelopedchemiluminescenceimmunoassay
AT hartwiglea serodiagnosisofantiglomerularbasementmembranediseaseusinganewlydevelopedchemiluminescenceimmunoassay
AT dahnrichcornelia serodiagnosisofantiglomerularbasementmembranediseaseusinganewlydevelopedchemiluminescenceimmunoassay
AT schlumbergerwolfgang serodiagnosisofantiglomerularbasementmembranediseaseusinganewlydevelopedchemiluminescenceimmunoassay